BREAST CANCER

Experts in breast oncology review 3 clinical cases of HER2+ breast cancer and discuss individualized treatment approaches for each patient.

The combination of atezolizumab and paclitaxel was not effective for the treatment of patients with treatment-naïve inoperable locally advanced or metastatic triple-negative breast cancer, according to an FDA alert.

The FDA granted a Priority Review to the New Drug Application for oral paclitaxel with encequidar for the treatment of patients with metastatic breast cancer.

Treatment with tesetaxel in combination with capecitabine led to an improvement in progression-free survival as treatment of patients with metastatic breast cancer compared with single-agent capecitabine, meeting the primary end point of the phase 3 CONTESSA study.

Leronlimab, demonstrated improvement in total clinical symptom score at day 3 in patients with mild-to-moderate symptoms from coronavirus disease 2019.

The phase 3 IMpassion131 trial investigating atezolizumab plus paclitaxel versus placebo plus paclitaxel did not its primary end point of progression-free survival and was not statistically significant in the first line for patients with metastatic triple-negative breast cancer who had PD-L1-positive disease.